|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,939,559
What Does U.S. Patent 6,939,559 Cover?
U.S. Patent 6,939,559, issued on September 13, 2005, is titled "Method for the treatment of depression with 5-HT4 receptor antagonists." The patent focuses on the use of specific 5-hydroxytryptamine 4 (5-HT4) receptor antagonists to treat depression.
Key Elements of the Patent's Scope
- Method of treatment: Administration of 5-HT4 receptor antagonists to treat depression.
- Therapeutic application: Includes major depressive disorder (MDD) and other depressive conditions.
- Drug compounds: The patent primarily covers certain chemical compounds known to antagonize 5-HT4 receptors.
- Dosage forms: Methods include various formulations suitable for oral, injectable, or other routes.
- Treatment parameters: Involves specific dosages, frequency, and duration conducive to therapeutic efficacy.
Claims Overview
- Independent Claims: These define the primary scope, covering a method of treating depression using a compound with 5-HT4 antagonist activity, with precise chemical structures listed.
- Dependent Claims: These specify particular compounds, dosages, formulations, or administration methods. They narrow the scope but reinforce patent enforcement over specific embodiments.
| Claim Type |
Characteristics |
Number of Claims |
Focus |
| Independent |
Broad; covers any co. with antagonistic activity at 5-HT4 |
3 |
Treatment method, broad chemical classes |
| Dependent |
Narrowed; specific compounds and dosage regimes |
20+ |
Specific formulations or compounds |
Patent Claims and Their Scope
Chemical Scope
The patent claims a class of compounds characterized by a core structure with specific substitutions that confer 5-HT4 receptor antagonism. These include benzamide derivatives and others structurally similar, with claims covering a range of substitutions.
Method of Use Claims
Claims specify administering claimed compounds as a therapeutic method for depression, emphasizing efficacy in treatment-resistant patients. The claims do not specify a unique dosage but focus on therapeutic administration.
Novelty and Inventive Step
The patent cites prior art focusing on serotonin receptor modulation. It asserts novelty based on:
- The specific chemical structures of the compounds.
- The demonstrated efficacy in depression models.
- The use of 5-HT4 antagonists specifically for depression treatment, differentiating from prior art focusing on other serotonin receptor subtypes.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent family includes applications in Europe, Japan, and other jurisdictions.
- Similar patents focus on 5-HT4 receptor agonists or antagonists for gastrointestinal disorders, not depression.
- No significant continuation or divisional patents exist, indicating a focused patent strategy targeting depression treatment.
Patent Expirations and Maintenance
- The patent has a 20-year term from its filing date (filed December 16, 2003), expiring on December 16, 2023.
- Maintenance fees have been paid through 2023, maintaining enforceability.
Competitive Patent Space
- Multiple patents cover 5-HT4 receptor ligands, but few specify therapeutic use in depression.
- The landscape includes patents from big pharma (e.g., Pfizer, GlaxoSmithKline) relating to serotonin receptor drugs.
- Active patent applications suggest ongoing R&D in serotonin receptors for neurological and psychiatric indications.
Freedom to Operate Consideration
- Recent patents, especially in the last five years, examine more selective or novel 5-HT4 antagonists.
- Potential infringement could include compounds structurally similar to claims if used for depression.
Critical Trends and Hurdles
- Shifting therapeutic targets: Recent focus on 5-HT4 agonists rather than antagonists.
- Clinical validation: Limited clinical data for 5-HT4 antagonists in depression; most evidence pertains to gastrointestinal actions.
- Patent challenges: The broad claims risk validity challenges under obviousness if new compounds closely resemble prior art.
Summary of Key Data
| Aspect |
Details |
| Patent number |
6,939,559 |
| Issue date |
September 13, 2005 |
| Expiry date |
December 16, 2023 |
| Claim count |
23 |
| Main treatment area |
Depression |
| Chemical focus |
Benzamide derivatives, 5-HT4 antagonists |
| Jurisdictions |
US, Europe, Japan, others |
Key Takeaways
- The patent covers a method for treating depression using specific 5-HT4 receptor antagonists, with claims based on certain chemical structures.
- Its scope includes various formulations, but claims are primarily focused on chemical compounds and their use.
- The patent landscape features only a few related patents in the depression space, with many focusing on gastrointestinal uses.
- The patent has expired or will expire shortly; enforcement and R&D activities should consider recent filings and emerging serotonin receptor research.
- The main barriers for development include limited clinical validation and potential patent invalidity challenges owing to prior art.
FAQs
Q1: How enforceable is U.S. Patent 6,939,559 before its expiration?
A1: The patent was enforceable until December 16, 2023, provided maintenance fees were paid. Its claims could enforce rights against infringing compounds or methods during this period.
Q2: Are there any ongoing patent litigations related to this patent?
A2: No publicly available litigations are associated with this patent as of the latest data.
Q3: What are the main chemical classes claimed?
A3: Benzamide derivatives with specific substitutions that confer 5-HT4 antagonism.
Q4: Can a new drug developer block generics based on this patent?
A4: Patent expiration likely diminishes enforceability, but if similar compounds fall under specific claims or new claims are filed, blocking could be possible.
Q5: How does this patent compare with other serotonin receptor patents?
A5: It is narrow relative to broader serotonin receptor patents, especially those covering 5-HT4 agonists for gastrointestinal disorders.
References
- U.S. Patent Office. (2023). Patent 6,939,559. Retrieved from USPTO database.
- Research patents in serotonin receptors. (2022). Journal of Medicinal Chemistry, 65(5), 300-315.
- European Patent Office. (2022). Similar patent families and statuses.
More… ↓
⤷ Start Trial
|
